ArticleProceedings of the National Academy of Sciences of the United States of America2022
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- CDK8/19 inhibition prevents adaptive resistance to CDK4/6 inhibitors in vitro and in vivo.Cell reports. Medicine · 2026Article
- CMGC Kinases in Viral Infection and Human Disease.Pathogens (Basel, Switzerland) · 2026Review
- Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition.JCI insight · 2026Article
- EMP3 Expression in HER2-Enriched Breast Cancer is Linked to PI3K/AKT Signaling and Indicates Poor Prognosis.Genetics research · 2026Article
- Targeting CDK8 dually enhances paclitaxel antitumor efficacy and alleviates chemotherapy-induced peripheral neuropathy in breast cancer.Frontiers in pharmacology · 2026Article
- AlphaFold for Docking Screens.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Dual Role of Diallyl Disulfide (DADS) on Invasive Potential and β-Catenin Dynamics in HER2-Positive Breast Cancer Cells.Cancers · 2025Article
- Targeting Transcriptional Cyclin-Dependent Kinases in Cancer.Molecular cancer therapeutics · 2025Review
- The role of CDK8 gene polymorphisms in bladder cancer susceptibility and prognosis: a study in the Chinese Han population.BMC cancer · 2025Article
- Article
- CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells.Cell death discovery · 2025Article
- Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.Signal transduction and targeted therapy · 2025Review
- The Cyclin-Dependent Kinase 8 Inhibitor E966-0530-45418 Attenuates Pulmonary FibrosisInternational journal of biological sciences · 2025Article
- Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- STAT3: Key targets of growth-promoting receptor positive breast cancer.Cancer cell international · 2024Review
- Special Issue "Novel Chemical Tools for Targeted Cancer Therapy".International journal of molecular sciences · 2024Article
- Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.The Journal of clinical investigation · 2024Article
- Unveiling the impact of CDK8 on tumor progression: mechanisms and therapeutic strategies.Frontiers in pharmacology · 2024Review
- A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov.Discover oncology · 2023Article
- CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins.Nucleic acids research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 3 countries.
Xiaokai DingDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.
Amanda C SharkoDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.
Martina S J McDermottDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.
Gary P SchoolsDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.
Alexander ChumanevichDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.ORCID 0000-0002-0612-1765
Hao JiDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.
Jing LiDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.ORCID 0000-0003-2065-9040
Li ZhangDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.
Zachary T MackDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.
Vitali SikirzhytskiDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.
Michael ShtutmanDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.ORCID 0000-0002-2458-3226
Laura IversNational Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
Norma O'DonovanNational Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
John CrownNational Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
Balázs GyőrffyDepartment of Bioinformatics, Semmelweis University, Budapest, H-1085, Hungary.ORCID 0000-0002-5772-3766
Mengqian ChenDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.ORCID 0000-0003-1706-9509
Igor B RoninsonDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.ORCID 0000-0002-9211-1327
Eugenia V BroudeDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, 715 Sumter St., Columbia, SC, 29208.ORCID 0000-0002-9180-7111
University of South Carolina Sumter · USDublin City University · IESemmelweis University · HU
Funding
Targeting NMDA Receptors and Brain Estradiol to Rescue Memory in Aging FemalesP20GM109091 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI RONINSON, IGOR B · 2014 to 2024
$25.2MPreventing adaptive drug resistance through Mediator kinase inhibitionR01CA266027 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Hexin Chen, Mengqian Chen · 2022 to 2026
$3.0MCDK8/19 inhibitors for therapy of advanced prostate cancerR44CA203184 · NCI · SENEX BIOTECHNOLOGY, INC. · PI CHEN, MENGQIAN, LILLY, MICHAEL B · 2020 to 2021
$2.0MCDK8/19 inhibitor for the treatment of HER2+ breast cancerR43CA221485 · NCI · SENEX BIOTECHNOLOGY, INC. · PI BROUDE, EUGENIA V, PORTER, DONALD C. · 2017 to 2017
$300kEnhancing cytarabine efficacy in leukemia through CDK8/19 inhibitionR43CA213629 · NCI · SENEX BIOTECHNOLOGY, INC. · PI PORTER, DONALD C. · 2017 to 2017
$300kNCI NIH HHS R01 CA266027NCI NIH HHS R43 CA213629NCI NIH HHS R43 CA221485NCI NIH HHS R44 CA203184NIGMS NIH HHS P20 GM109091
Abstract
Breast cancers (BrCas) that overexpress oncogenic tyrosine kinase receptor HER2 are treated with HER2-targeting antibodies (such as trastuzumab) or small-molecule kinase inhibitors (such as lapatinib). However, most patients with metastatic HER2
Indexed as
Breast NeoplasmsCyclin-Dependent Kinase 8Cyclin-Dependent KinasesDrug Resistance, NeoplasmProtein Kinase InhibitorsAnimalsAntineoplastic AgentsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansImmediate-Early ProteinsLapatinibMicePhosphatidylinositol 3-KinasesTrastuzumabAntineoplastic AgentsBTG2 protein, humanCDK19 protein, humanCDK8 protein, humanCyclin-Dependent Kinase 8Cyclin-Dependent KinasesErb-b2 Receptor Tyrosine KinasesImmediate-Early ProteinsLapatinibPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsTrastuzumabTumor Suppressor ProteinsCDK8/19HER2lapatinibMediator kinasetrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.